NCT06307080Recruiting
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
Source: ClinicalTrials.gov · Last updated 9 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy. 3. Transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 18 Feb 2024
- Start date
- 8 Oct 2023
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Diseases
- Pancreatic cancer
- NCT number
- NCT06307080
What you commit to
- Study type: Interventional
- Planned participants: 12
- From 8 Oct 2023 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- serious heart, lung, liver and kidney dysfunction and coagulation dysfunction;
- Uncontrolled co-morbidities, including poorly controlled hypertension or diabetes, persistent active infections, or mental illness or social conditions that may affect participants' compliance with the study;
Other
- Liver function Child-Pugh grade C, severe jaundice, especially obstructive jaundice;
- The liver is significantly atrophy, the tumor is too large, and the ablation range needs to reach one-third of the liver volume;
- Expected survival \< 3 months;
- refractory ascites, pleural fluid or bad fluid;
- Pregnancy or breastfeeding;
- The researcher considers that there are any other factors that are not suitable for inclusion or affect the participant's participation in the study.
Who the study is looking for
- age 18-70 years old, gender is not limited;
- Newly diagnosed pancreatic cancer with liver metastasis confirmed by pathology or consistent with clinical diagnosis, and no metastases to organs other than the liver;
- Imaging evaluable tumors with safe access to puncture;
- The number of half liver tumors ≤3 and the size of each tumor ≤3 cm;
- ECOG PS score ≤2 points, expected survival \> 3 months.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai General Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.